Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Bin Wang, Qing Yin, Yu-Chen Han, Min Wu, Zuo-Lin Li, Yan Tu, Le-ting Zhou, Qing Wei, Hong Liu, Ri-Ning Tang, Jing-Yuan Cao, Lin-Li Lv & Bi-Cheng Liu. (2020) Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Renal Failure 42:1, pages 912-925.
Read now
Read now
Articles from other publishers (17)
Francesco Locatelli, Roberto Minutolo, Luca De Nicola & Lucia Del Vecchio. (2022) Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. Drugs 82:16, pages 1565-1589.
Crossref
Crossref
Yaling Zhang, Song Ren, Hen Xue, Amanda Y Wang, Yang Zou, Yanrong Cai, Jingdong He, Xiaoling Yuan, Feifei Jiang, Jinxi Wei, Dongmei Yang, Dong He, Shide Hu, Min Lei, Fei Deng, Jin Chen, Xia Wang, Qiang He, Guisen Li & Daqing Hong. (2021) Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study. BMC Nephrology 22:1.
Crossref
Crossref
Masaomi Nangaku, Youssef M K Farag, Emil deGoma, Wenli Luo, Dennis Vargo & Zeeshan Khawaja. (2021) Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrology Dialysis Transplantation 36:7, pages 1244-1252.
Crossref
Crossref
Daniel W. Coyne & Robert Fleming. (2021) Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?. Journal of the American Society of Nephrology 32:1, pages 6-8.
Crossref
Crossref
Matthew R. Weir. (2021) Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. American Journal of Nephrology 52:6, pages 450-466.
Crossref
Crossref
Borut Cizman, Helen T. Smith, Rodrigo Refoios Camejo, Linda Casillas, Harjeet Dhillon, Fan Mu, Eric Wu, Jipan Xie, Peter Zuckerman & Daniel Coyne. (2020) Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. Kidney Medicine 2:5, pages 589-599.e1.
Crossref
Crossref
Wesley Hayes. (2018) Measurement of iron status in chronic kidney disease. Pediatric Nephrology 34:4, pages 605-613.
Crossref
Crossref
Michaela Kohlová, Célia Gomes Amorim, Alberto Araújo, Alice Santos-Silva, Petr Solich & Maria Conceição B. S. M. Montenegro. (2018) The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. Journal of Artificial Organs 22:1, pages 14-28.
Crossref
Crossref
Norishi Ueda & Kazuya Takasawa. (2018) Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients 10:9, pages 1173.
Crossref
Crossref
Borut Cizman, Andy P. Sykes, Gitanjali Paul, Steven Zeig & Alexander R. Cobitz. (2018) An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. Kidney International Reports 3:4, pages 841-850.
Crossref
Crossref
Sarita Bajaj, BrijMohan Makkar, VinodK Abichandani, PradeepG Talwalkar, Banshi Saboo, SS Srikanta, Ashok Das, Sruti Chandrasekaran, PVenkata Krishnan, Arun Shah, Georgi Abraham, Pankaj Tikku & Sushil Kumar. (2016) Management of anemia in patients with diabetic kidney disease: A consensus statement. Indian Journal of Endocrinology and Metabolism 20:2, pages 268.
Crossref
Crossref
Afshin Gharekhani, Mohammad-Reza Khatami, Simin Dashti-Khavidaki, Effat Razeghi, Alireza Abdollahi, Seyed-Saeed Hashemi-Nazari & Mohammad-Ali Mansournia. (2014) Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. DARU Journal of Pharmaceutical Sciences 22:1.
Crossref
Crossref
Lucile Mercadel, Marie Metzger, Jean Philippe Haymann, Eric Thervet, Jean-Jacques Boffa, Martin Flamant, François Vrtovsnik, Pascal Houillier, Marc Froissart & Bénédicte Stengel. (2014) The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease. PLoS ONE 9:6, pages e99781.
Crossref
Crossref
Kazuya Takasawa, Naohisa Tomosugi, Chikako Takaeda, Teiryo Maeda & Norishi Ueda. (2014) Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron Extra 4:1, pages 55-63.
Crossref
Crossref
A. Icardi, E. Paoletti, L. De Nicola, S. Mazzaferro, R. Russo & M. Cozzolino. (2013) Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrology Dialysis Transplantation 28:7, pages 1672-1679.
Crossref
Crossref
Borja Quiroga, Eduardo Verde, Soraya Abad, Almudena Vega, Marian Goicoechea, Javier Reque, Juan M. López-Gómez & José Luño. (2013) Detection of patients at high risk for non-occlusive mesenteric ischemia in hemodialysis. Journal of Surgical Research 180:1, pages 51-55.
Crossref
Crossref
Wei Tan, En Tian, Bin Tang, Ling Zhong, Wei Hua, Xianhong Jiang, Zhuoying Li, Yudong Sun, Ying Hao, Jin He, Liangping He, Xiaohui Wang & Jurong Yang. (2022) Design and Methodology of the Impact of Roxadustat on Left Ventricular Hypertrophy in Hemodialysis Patients (ROFIH-HD): A Multicenter, Prospective, Randomized Controlled Trial. SSRN Electronic Journal.
Crossref
Crossref